During his brief bid to become the Republican presidential nominee in 2023, Ramaswamy invoked his biotech credentials to ...

This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling ...

Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these ...

As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could ...

Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted ...

After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more ...

The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its ...

The investor narrative around Eli Lilly is deeply rooted in obesity. The blockbuster GLP-1 medications Mounjaro and Zepbound are driving the large pharma’s gains in revenue, which rose 39% ...

Pharmaceuticals enable modern healthcare by helping to prevent, manage, and cure disease, but growing demand is increasing their impact on the environment. For oral drug delivery, medicines must be ...

However, despite this progress, the bioprocessing industry still struggles to use this data in a way that consistently ...

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the ...

Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its ...